The drug, liraglutide, is sold under the brand names Victoza and Saxenda. Patents for Victoza and Saxenda have now expired. So other drug companies are working to develop "generic" versions.

Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

The retrospective study points to fewer suicidal thoughts or attempts among adolescents taking semaglutide or liraglutide.

CVS Caremark and Express Scripts, along with GoodRx and others, are accused of working together to suppress reimbursements to independent pharmacies in at least three class-action lawsuits. Also, Hims ...

Ozempic (semaglutide) and Victoza (liraglutide) are prescription drugs used to treat type 2 diabetes and reduce the risk of cardiovascular problems. Both drugs come as an injection. Ozempic and ...

Lexaria Bioscience (LEXX) has received partial 12-week body weight results from the recently completed animal study WEIGHT-A24-1. Lexaria is ...

Lexaria Bioscience (LEXX) received partial 12-week blood sugar results from the recently completed animal study WEIGHT-A24-1. The company said, ...

Groups G and H used pure GLP-1 drugs (semaglutide and liraglutide respectively) in DehydraTECH compositions Recalculations led to slight changes from earlier reported data Lexaria is strongly ...

Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. How much weight a person loses on liraglutide or ...

Diabetes Care. 2015;38(6):1058-1066. The safety profile of liraglutide is under continuous surveillance through meticulous routine pharmacovigilance, with any cases of pancreatitis being analyzed ...

The drug, liraglutide, is sold under the brand names Victoza and Saxenda. Patents for Victoza and Saxenda have now expried. So other drug companies are working to develop “generic” versions.